glp-1 cirrhosis The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis

GLP-1s are back in the news — but this is a conversation we've explored on our channel before. From weight loss to heart, kidney, liver, sleep and metabolic health, the science is

27.19

★★★★☆4.8 (126)

Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis

21.59

★★★★★4.9 (98)

GLP-1 and fatty liver disease. Non-alcoholic fatty liver disease affects 25% of adults worldwide. It is directly linked to excess weight and insulin resistance. Left untreated, it can progress to cirrhosis and

25.74

★★★★★5.0 (157)

GLP-1 and Glucagon Receptor Dual Agonists in the Management of Metabolic Dysfunction-associated Steatotic Disease (MASLD) | Current Hepatology Reports

27.72

★★★★★4.7 (84)

GLP-1 Drugs May Trigger Muscle Loss In Cirrhosis Patients: Study

24.71

★★★★★4.9 (203)

Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)

23.05

★★★★★5.0 (176)

Exploring Glucagon-like Peptide-1 receptor agonist (GLP-1 RA) Use in Patients with Cirrhosis

23.41

★★★★★4.8 (132)